Log in
Enquire now
‌

US Patent 10301282 Polymorphic form X of nilotinib dihydrochloride hydrate

Patent 10301282 was granted and assigned to Cipla on May, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Cipla
Cipla
Current Assignee
Cipla
Cipla
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10301282
Patent Inventor Names
Srinivas Laxminarayan Pathi0
Dharmaraj Ramachandra Rao0
Geena Malhotra0
Manish Gopaldas Gangrade0
Venugopalarao Chinimilli0
Date of Patent
May 28, 2019
Patent Application Number
15559325
Date Filed
March 21, 2016
Patent Citations Received
‌
US Patent 12064428 Kinase inhibitor salts and compositions thereof
0
‌
US Patent 10940149 Kinase inhibitor salts and compositions thereof
‌
US Patent 11007195 Kinase inhibitor salts, and compositions thereof
‌
US Patent 11052088 Kinase inhibitor salts, and compositions thereof
‌
US Patent 12064430 Kinase inhibitor salts and compositions thereof
0
Patent Primary Examiner
‌
Emily A Bernhardt
Patent abstract

The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10301282 Polymorphic form X of nilotinib dihydrochloride hydrate

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.